NASDAQ:NEUP
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?
Key Facts: - Neuphoria shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial Investing. The AFFIRM-1 trial missed both primary and secondary endpoints,…
Company hubNASDAQ:NEUP
Neuphoria (NEUP) Stock News & Analysis
Follow the latest Neuphoria (NEUP) company news, earnings coverage and investor analysis from TechStock².
Save this hub to your TS2 Signalbook account.
- Latest update
- Articles in this hub
- 1
- Last 30 days
- 0
What investors are watching
- Earnings, guidance and financial performance
- Valuation, trading activity and market sentiment
- Strategy, catalysts and company-specific risks
All coverage